Robinson Byron has filed 3 insider transactions across 1 company since January 2024.
Most recent transaction: a grant/award of 28000 shares of Janux Therapeutics, Inc. ($JANX) on January 02, 2025.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 2, 2025 | Janux Therapeutics, Inc. | $JANX | Robinson Byron | Chief Strategy Officer | A | Common Stock | 28000 | $0.00 | 28,000.0000 | 53,751,480 | 9999.99% | 0.05% |
| Jan. 2, 2025 | Janux Therapeutics, Inc. | $JANX | Robinson Byron | Chief Strategy Officer | A | Stock option (right to buy) | 98000 | $0.00 | 98,000.0000 | 53,751,480 | 9999.99% | 0.18% |
| Jan. 2, 2024 | Janux Therapeutics, Inc. | $JANX | Robinson Byron | Chief Strategy Officer | A | Stock Option (right to buy) | 151500 | $0.00 | 151,500.0000 | 44,016,283 | 9999.99% | 0.34% |